Dr. Elizabeth Nielson
Dr. Nielson is a psychologist and therapist on clinical trials of psilocybin-assisted treatment of alcohol use disorder and treatment-resistant depression, and currently serves as a site Co-Principal Investigator for the MAPS sponsored Phase 3 Study of MDMA-assisted therapy for PTSD (MAPP2). Working at 3 leading clinical research sites in New York City over the past 7 years, she has built a unique expertise in the practice of psychedelic-assisted therapy, and in training and mentoring fellow clinicians in the delivery of psychedelic-assisted therapy in research settings. Dr. Nielson’s research includes qualitative studies of patient experiences in psychedelic-assisted therapy, interview studies of psychedelic therapists, and research on the historical use of LSD in psychotherapist training. In her formal higher education Dr. Nielson studied art, psychology, and evidence-based interventions for drug and alcohol use, including harm reduction, motivational interviewing, community reinforcement, and mindfulness-based therapy. She has pursued extensive post-graduate coursework in foreign languages, Buddhist psychology, and meditation and contemplative practice. Dr. Nielson Co-founded Fluence, a psychedelic-assisted therapy and integration education program for clinicians, in 2019 to bring professional education about psychedelic-assisted therapies to clinicians and broaden access to the field while enhancing the diversity of trained clinicians. She held a post-doctoral fellowship in psychodynamic therapy at Adelphi University and a NIDA funded post-doctoral fellowship in the Behavioral Science Training Program in Drug Abuse Research at NDRI/NYU School of Nursing before her appointment as Assistant Professor of Clinical Medical Psychology (in Psychiatry) at Columbia University Irving Medical Center in 2020.
While research clearly acknowledges the therapist’s indispensable role before, during, and afte…